Benjamin Hohl insider trades: Enliven Therapeutics (ELVN) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Benjamin reports to the SEC
Open-market buys and sales
41 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | ELVN | ↓ Sell | 6,018 | $38.48 | $232K | Direct | Oct 21, 2026 (2d) |
| Sep 17, 2026 | ELVN | ↓ Sell | 6,018 | $50.35 | $303K | Direct | Sep 21, 2026 (4d) |
| Aug 17, 2026 | ELVN | ↓ Sell | 6,018 | $58.58 | $353K | Direct | Aug 19, 2026 (2d) |
| Jul 17, 2026 | ELVN | ↓ Sell | 6,018 | $52.64 | $317K | Direct | Jul 21, 2026 (4d) |
| Jun 17, 2026 | ELVN | ↓ Sell | 6,018 | $43.80 | $264K | Direct | Jun 22, 2026 (5d) |
| Mar 6, 2026 | ELVN | ↓ Sell | 10,000 | $29.58 | $296K | Direct | Mar 10, 2026 (4d) |
| Sep 29, 2025 | ELVN | ↓ Sell | 3,250 | $20.40 | $66K | Direct | Oct 1, 2025 (2d) |
| Aug 27, 2025 | ELVN | ↓ Sell | 3,250 | $20.63 | $67K | Direct | Aug 29, 2025 (2d) |
| Jul 28, 2025 | ELVN | ↓ Sell | 3,250 | $20.46 | $67K | Direct | Jul 30, 2025 (2d) |
| Jul 10, 2025 | ELVN | ↓ Sell | 1,000 | $22.66 | $23K | Direct | Jul 14, 2025 (4d) |
| Jun 27, 2025 | ELVN | ↓ Sell | 3,250 | $20.91 | $68K | Direct | Jul 1, 2025 (4d) |
| Jun 13, 2025 | ELVN | ↓ Sell | 3,000 | $22.55 | $68K | Direct | Jun 17, 2025 (4d) |
| May 27, 2025 | ELVN | ↓ Sell | 3,250 | $16.18 | $53K | Direct | May 29, 2025 (2d) |
| Apr 28, 2025 | ELVN | ↓ Sell | 3,250 | $18.69 | $61K | Direct | Apr 30, 2025 (2d) |
| Mar 27, 2025 | ELVN | ↓ Sell | 3,250 | $21.33 | $69K | Direct | Mar 31, 2025 (4d) |
| Mar 24, 2025 | ELVN | ↓ Sell | 1,000 | $22.50 | $23K | Direct | Mar 26, 2025 (2d) |
| Feb 27, 2025 | ELVN | ↓ Sell | 3,250 | $20.41 | $66K | Direct | Mar 3, 2025 (4d) |
| Feb 5, 2025 | ELVN | ↓ Sell | 1,000 | $22.52 | $23K | Direct | Feb 7, 2025 (2d) |
| Jan 27, 2025 | ELVN | ↓ Sell | 3,250 | $21.59 | $70K | Direct | Jan 29, 2025 (2d) |
| Jan 3, 2025 | ELVN | ↓ Sell | 1,000 | $25.04 | $25K | Direct | Jan 7, 2025 (4d) |
| Dec 30, 2024 | ELVN | ↓ Sell | 4,250 | $22.23 | $94K | Direct | Dec 31, 2024 (1d) |
| Nov 27, 2024 | ELVN | ↓ Sell | 5,250 | $24.89 | $131K | Direct | Dec 2, 2024 (5d) |
| Oct 28, 2024 | ELVN | ↓ Sell | 6,250 | $28.56 | $178K | Direct | Oct 30, 2024 (2d) |
| Oct 18, 2024 | ELVN | ↓ Sell | 814 | $30.00 | $24K | Direct | Oct 22, 2024 (4d) |
| Oct 7, 2024 | ELVN | ↓ Sell | 11,488 | $27.51 | $316K | Direct | Oct 8, 2024 (1d) |
| Oct 1, 2024 | ELVN | ↓ Sell | 521 | $27.54 | $14K | Direct | Oct 3, 2024 (2d) |
| Sep 30, 2024 | ELVN | ↓ Sell | 6,250 | $24.61 | $154K | Direct | Oct 1, 2024 (1d) |
| Aug 27, 2024 | ELVN | ↓ Sell | 4,250 | $22.54 | $96K | Direct | Aug 29, 2024 (2d) |
| Jul 31, 2024 | ELVN | ↓ Sell | 991 | $27.53 | $27K | Direct | Aug 2, 2024 (2d) |
| Jul 29, 2024 | ELVN | ↓ Sell | 5,250 | $26.68 | $140K | Direct | Jul 31, 2024 (2d) |
| Jul 12, 2024 | ELVN | ↓ Sell | 3,000 | $25.07 | $75K | Direct | Jul 16, 2024 (4d) |
| Jun 27, 2024 | ELVN | ↓ Sell | 4,250 | $22.57 | $96K | Direct | Jul 1, 2024 (4d) |
| May 28, 2024 | ELVN | ↓ Sell | 4,250 | $23.18 | $99K | Direct | May 30, 2024 (2d) |
| May 3, 2024 | ELVN | ↓ Sell | 1,000 | $22.50 | $23K | Direct | May 7, 2024 (4d) |
| Apr 29, 2024 | ELVN | ↓ Sell | 3,250 | $16.97 | $55K | Direct | May 1, 2024 (2d) |
| Apr 11, 2024 | ELVN | ↓ Sell | 14,000 | $24.72 | $346K | Direct | Apr 15, 2024 (4d) |
| Mar 27, 2024 | ELVN | ↓ Sell | 3,250 | $18.25 | $59K | Direct | Mar 29, 2024 (2d) |
| Feb 27, 2024 | ELVN | ↓ Sell | 3,250 | $16.97 | $55K | Direct | Feb 29, 2024 (2d) |
| Jan 29, 2024 | ELVN | ↓ Sell | 3,250 | $15.81 | $51K | Direct | Jan 31, 2024 (2d) |
| Jan 2, 2024 | ELVN | ↓ Sell | 11,870 | $15.02 | $178K | Direct | Jan 2, 2024 (0d) |
| Dec 26, 2023 | ELVN | ↓ Sell | 1,130 | $15.07 | $17K | Direct | Dec 27, 2023 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ELVN insiders
Open-market trades in the last 12 months
About Benjamin Hohl's insider trades
Benjamin Hohl is Chief Financial Officer at Enliven Therapeutics (ELVN). Since Dec 26, 2023, Benjamin has reported no open-market purchases and 41 sales worth $4.7M on SEC Form 4. In the last 12 months: 6 sales ($1.8M).
Their filings also include option exercises (41 filings), grants and awards (5 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ELVN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.